Skip to content

Use of Expressive Writing in Irritable Bowel Syndrome (IBS)

Use of Expressive Writing in Irritable Bowel Syndrome (IBS)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01192672
Enrollment
197
Registered
2010-09-01
Start date
2008-09-30
Completion date
2010-11-30
Last updated
2017-03-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Irritable Bowel Syndrome

Brief summary

The purpose of this study is to test whether disease-related expressive writing is effective in the treatment of Irritable Bowel Syndrome (IBS).

Detailed description

Expressive writing involves writing about traumatic, stressful or emotional events. Expressive writing, for as little as 3-5 sessions of 20 minutes, has been found to improve both physical and psychological health based on health outcome measures such as number of doctor's visits and hospital days, blood pressure control, lung and immune function, and pain. Given its simplicity, and obvious advantages in terms of cost efficiency, expressive writing appears to have great potential as a therapeutic tool or as a means of self-help, either alone or as an adjunct to traditional therapies. This modality has not been studied in irritable bowel syndrome (IBS), a common gastrointestinal condition, which is lacking well-defined etiology or treatments and is best understood in a biopsychosocial context.

Interventions

BEHAVIORALExpressive Writing

Subjects in the Intervention were instructed to write for 30-minute intervals for 4 consecutive days about their deepest thoughts and feelings related to their Irritable Bowel Syndrome.

BEHAVIORALControl Writing

Subjects were asked to write about the actions they performed during the last 24 hours. They were asked not to write about their feelings or thoughts related to these actions.

Sponsors

Takeda Pharmaceuticals North America, Inc.
CollaboratorINDUSTRY
Boston University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Clinical diagnosis of Irritable Bowel syndrome

Exclusion criteria

* Non-English Speakers

Design outcomes

Primary

MeasureTime frameDescription
IBS-Specific Quality of Life (IBS-QOL)3 monthsIBSQOL is a measure of IBS - specific quality of life.

Secondary

MeasureTime frameDescription
Health care Utilization (HCU)3 monthsHCU is a measure of frequency and type of health care received for IBS
IBSSS3 monthsIBSSS provides a disease severity measure
CT33 monthsMeasure of health-related cognition (catastrophizing or maladaptive coping,and patients' perceived ability to control symptoms)
Cognitive Scale for Functional Bowel Disorders (CGFBD)3 monthsMeasure of IBS related cognitions.
Writing Evaluation Questionnaire (WEQ)3 monthsThe WEQ measure obtains subjects' reflections about their writing experience.
Demographics (DEM-MED)BaselineDemographic information

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026